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Treatment of epileptic seizures as medical
emergencies: a prospective analysis of a decision tree
for nonmedically trained staff
EVELYNE PEETERS
Avenue Cle´mentine 2, B-1190 Brussels, Belgium∗
The aim of this study was to evaluate the benefi of treating every epileptic seizure as an emergency and to propose a decision tree
for use by nonmedical staff. Published literature on emergency medical treatment for seizures was reviewed. A detailed decision
tree was developed for use by nonmedical staff. Its effectiveness was prospectively analysed over 16 months. Each seizure was
logged, and its duration and severity were recorded. Type, dose, and time of antiepileptic treatment were noted. Results were
compared with a 6-month retrospective review. Initiation of antiepileptic drug treatment 5 or 7 minutes after seizure onset was
indicated in the tree. Rectal diazepam or lorazepam, or fast-dissolving lorazepam was used. Use of the decision tree resulted in
decreased duration of seizures, which lasted up to 18 hours in the retrospective review compared with only 37 minutes in the
prospective study. Using this tree, nonmedical staff can appropriately treat adults experiencing seizures. Duration, severity, and
frequency of seizures decreased when every seizure was treated as a medical emergency. Implementation of a decision tree is
recommended for establishments with patients prone to seizures. It can also be taught to caregivers and parents of patients with
well-known epilepsy.
c© 2000 BEA Trading Ltd
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INTRODUCTION
Epilepsy is the most common serious neurologic dis-
order, and patients may die as a direct result of it1.
Although most seizures are self-limiting, a prolonged
seizure can evolve into status epilepticus, define as a
life-threatening seizure lasting 30 minutes or more2.
The overall mortality rate of patients experiencing sta-
tus epilepticus is estimated to be 20%3. Morbidity is
characterized by intellectual dysfunction, neurologic
deficits and chronic epilepsy. Epilepsy in general
is associated with an increased risk of death from a
variety of other causes, including suicide, sudden un-
explained death syndrome (SUDEP), and accidental
death. Due to the substantially increased risk of mor-
bidity and mortality, every epileptic seizure should be
treated as a potential major medical emergency2.
Based on clinical data, the risk of poor outcome is
higher as seizure duration increases 4, 5; thus, appro-
priate and timely treatment is critical 6, 7. The longer
a seizure remains untreated, the more difficul it is to
control with antiepileptic drug therapy 8, 9. In clinical
practice, antiepileptic drug administration is recom-
mended whenever seizure duration lasts 10 minutes,
and any patient who is still convulsing on arrival at
the emergency room should be treated aggressively2.
Rapid control of an initial seizure may prevent poten-
tial complications and progression to status epilepti-
cus.
In establishments for people with learning dif-
ficulties a reported 20–50% of residents have
epilepsy10, 11, and attending nonmedical personnel are
often confronted with patients experiencing seizures.
However, because they are not trained in manag-
ing seizures, emergency treatment is often delayed,
thereby placing the patient at increased risk of se-
rious clinical consequences. Thus, the development
of a detailed instructional tool to guide nonmedical
staff on the appropriate identificatio and management
of epileptic seizures is needed. The development of
such an instructional tool and a subsequent prospective
study using this tool in patients experiencing seizures
in establishment settings are reported in this paper.
MATERIALS AND METHODS
A comprehensive review was undertaken of the litera-
ture that would assist in the development of a decision
tree for emergency treatment of seizures. Informa-
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tion reviewed included the risk of prolonged seizures,
antiepileptic treatments available for use by nonmed-
ical staff, and the benefit and risks associated with
the pharmacology and route of administration of dif-
ferent emergency antiepileptic treatments. Based on
these data, an initial draft of a detailed decision tree
was developed and, over a 4-month period, was re-
vised several times before being implemented for use
within two establishments (Farra Clerlande, Ottignies,
Belgium and La Forestie`re, Brussels, Belgium).
From August 1, 1996 to November 30, 1997, a
prospective study was conducted to evaluate the util-
ity of the decision tree in guiding seizure treatment
and the effectiveness of the decision tree in controlling
epileptic seizures. Nonmedically trained staff were in-
structed on proper identificatio of epileptic seizures.
Verbal and written instructions on the provision of
antiepileptic treatment were provided to each staff
member. Per decision tree, drug treatment was admin-
istered, and factors including dose, time of treatment,
seizure type, duration, severity, and frequency were
recorded.
Results of the prospective study were compared
with that of a retrospective review study. In the retro-
spective review study, treatment and management
practices of epileptic seizures at two establishments
were identified and therapeutic outcomes over a 6-
month period (October 1, 1995–March 31, 1996) were
analysed. The frequency, duration, and severity of
seizures occurring in 20 patients with epilepsy were
identifie in medical records. All patients were at least
18 years of age, moderately to profoundly mentally
handicapped, and had been receiving maintenance
therapy with oral antiepileptic drugs.
RESULTS
Retrospective review
A total of 1100 seizures in 20 patients with learn-
ing difficultie with epilepsy had been identifie and
a 6-month retrospective analysis period undertaken
(Table 1). In many patients, seizures lasted only a
few seconds or minutes and were not continuous
or prolonged. Of the 1100 seizures, 1048 were iso-
lated seizures, and most patients who experienced pro-
longed seizures (>5 minutes) were not treated. The
other 52 were clusters of three to nine seizures, many
lasting for up to or more than 1 hour. The majority
of these cases were seizures with a loss of conscious-
ness, and no good recovery of consciousness between
intervals was obtained. In the 6-month review, a total
of two patients were hospitalized. Diagnoses of these
patients revealed that nine had an unknown origin of
encephalopathy, four had Lennox–Gastaut syndrome,
four had encephalitis, two had Down’s syndrome, and
one had an astrocytoma.
Development of the decision tree
The decision tree was designed for utilization in the
ambulatory setting, where complete respiratory and
cardiac assistance is unavailable. Based on the liter-
ature review, patients with seizures lasting longer than
10 minutes were found to be at high risk for neuro-
logic damage and poor outcome. Prolonged seizures
were define as generalized tonic–clonic seizures with
a duration of more than 5 minutes but less than 30 min-
utes. Clusters were define as three or more seizures
per hour. Therefore, to prevent neurological damage,
the decision tree was designed containing instructions
for nonmedically trained staff to provide antiepilep-
tic treatment if seizure duration exceeded 5 minutes
with loss of consciousness or 7 minutes without loss
of consciousness or if there was incomplete recovery
between seizures (Fig. 1).
In Europe, antiepileptic drugs that can be made
available to nonmedical staff include diazepam,
clobazam, clonazepam, and lorazepam. In the devel-
opment of the decision tree, considerations were given
to drug effica y and safety, available routes of admin-
istration, and ease of use. As a result, rectal diazepam
and lorazepam and sublingual lorazepam were deemed
appropriate and easy to use by nonmedical staff. The
rectal formulation of diazepam (1 ampule of 10 mg)
or lorazepam (1 ampule of 4 mg) was to be given
to patients who had a loss of consciousness during a
tonic–clonic seizure and did not recover during pre-
paration of medication. Rectal preparations were to be
administered by inserting a plastic syringe 2–4 cm into
the rectal cavity. Fast-dissolving sublingual lorazepam
(Expidetr 2.5 mg) was to be administered to patients
who did not have a loss of consciousness during their
seizure. For continuous, uncontrolled seizures, staff
members were advised to call emergency services im-
mediately and then allow at least 30 minutes after the
initial dose before administering another dose and an
additional 6 hours if a third dose was required.
In the 4-month period that the decision tree was
initially tested but still undergoing revisions, there
were 695 reported seizures (Table 1). The duration of
these seizures lasted from a few minutes to 90 min-
utes. Six hundred and seventy-eight of the seizures
were isolated seizures; 328 were seizures with loss of
consciousness and 350 were seizures without a loss of
consciousness. Of the patients experiencing prolonged
seizures (>5 minutes) with loss of consciousness (n =
25), 67% were treated with rectal diazepam, which re-
sulted in good recovery. Likewise, in those experienc-
ing seizures lasting up to 7 minutes without loss of
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Table 1: Seizure results.
6-Month retrospective review Implementation of the decision tree for a
4-month period
16-month prospective study
All types, assorted: 1100 seizures or
clusters, duration: a few seconds to 18 h
All types, assorted: 695 seizures or clusters,
duration: a few seconds to 1.5 h
All types, assorted: 1363 seizures or
clusters, duration: a few seconds to 37 min
1048 isolated seizures, duration: a few
seconds to 3 h
678 isolated seizures, duration: a few
seconds to 1.5 h
1279 isolated seizures, duration: a few
seconds to 37 min
−529 with loss of consciousness −328 with loss of consciousness −749 with loss of consciousness
127 itemized: 111 itemized: 749 itemized:
n = 23: 5–20 min (18.1%) n = 15: 5–15 min (13.5%) n = 720: <5 min
n = 6: 2–5 min (4.7%) n = 8: 2–5 min (7.2%) n = 9: >5 min with no interruption
n = 92: 1–2 min (72.4%) n = 60: 1–2 min (54.1%) during preparation of
n = 6: <1 min (4.7%) n = 28: <1 min (25.2%) injection→IRV→OK
n = 7: >5 min with no interruption
n = 11: >10 min treated by IRV→OK n = 10: >5 min treated by IRV→OK during preparation of
injection→IRT→OK
n = 13: >5 min interruption during
preparation of injection→
Texpr→OK
−519 with no loss of consciousness −350 with no loss of consciousness −530 without loss of consciousness
242 itemized: 169 itemized: 530 itemized:
n = 156: <7 min (64.5%) n = 112: <7 min n = 467: <7 min
n = 86: 7 min to 3 h, untreated n = 57: 7 min to 1.5 h n = 63: >7 min treated by Texpr
n = 6: >7 min, treated with 2.5 mg→OK
Texpr 1 mg
Result: 0→treated by IRV→OK
n = 13: >7 min, treated with
Texpr 2.5 mg→OK
52 clusters of 3–9 seizures, duration: a few
min to 18 h
17 clusters of 3 seizures <1 h 84 clusters of 3 seizures <1 h
4 clusters of 3–6 seizures, with loss of
consciousness, duration: 1 h without GRC
in the intervals→OK
3× 3 seizures with loss of consciousness
<5 min, no GRC between 2nd and
3rd→IRV→OK
13× 3 seizures with loss of consciousness
<5 min, GRC in the intervals→Texpr
2.5 mg as prevention
10 clusters of seizures, with loss of
consciousness, duration: a few min to 17.5 h
without GRC in the intervals, untreated, 1
hospitalization
10× 3 seizures with loss of consciousness
<5 min, no GRC between 2nd and 3rd,
untreated
15× 3 seizures with loss of consciousness
<5 min, no GRC between 2nd and
3rd→IRV→OK
1 cluster of 6 seizures, with loss of
consciousness, duration: 1 h without GRC
in the intervals→3 1/2 IRT at 15 min
interval→OK
2× 3 seizures with loss of consciousness
<5 min, GRC in the intervals, no prevention
1× 3 seizures with loss of consciousness
<5 min, no GRC between 2nd and
3rd→IRT→OK
2 clusters of 3 or 4 seizures, with loss of
consciousness, duration 1 h without GRC in
the intervals→IRV→OK
1× 3 seizures without loss of consciousness
<7 min, no prevention
55× 3 seizures without loss of
consciousness <7 min→Texpr 2.5 mg as
prevention
3 clusters of 6–9 seizures, with loss of
consciousness, duration: 95 to 190 min
without GRC in the intervals→IRT→OK
2/3
1× 3 seizures without loss of consciousness
<7 min→Texpr 2.5 mg as prevention
3 clusters of 6–9 seizures, with loss of
consciousness, duration: 270 to 360 min
without GRC in the intervals, different
attempts, no results. 1 hospitalization
10 clusters of seizures, with loss of
consciousness, duration: 25 min to 18 h
without GRC in the intervals, untreated
19 clusters of seizures, without loss of
consciousness, duration: 1–3 h, untreated.
Total hospitalizations: 2
Cluster: arbitrarily at least three seizures ≤60 min.
GRC = good recovery of consciousness; IRT = intrarectal Valiumr (diazepam); IRV = intrarectal Temestar (lorazepam); Texpr =
Temesta Expidetr.
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Fig. 1: Decision tree for use by nonmedical staff.
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consciousness (n = 76), 25% of treated patients had
good recovery. A total of 17 cluster seizures occurring
within 60 minutes were reported. Those treated with
rectal diazepam experienced good recovery.
Prospective analysis
A total of 1363 seizures were reported in the 16-
month prospective analysis (Table 1): 1279 isolated
seizures and 84 clusters of three seizures occurring
within 60 minutes. With the implementation of the de-
cision tree, patients experiencing prolonged or con-
tinuous seizures with loss of consciousness were
treated immediately at 5 minutes with rectal diazepam
or lorazepam. Patients experiencing seizures without
loss of consciousness were treated with lorazepam
(Expidetr 2.5 mg) at 7 minutes. Treatment of seizures
as medical emergencies reduced frequency, duration,
and severity (in comparison with results from the
retrospective review). In patients who had cluster
seizures with loss of consciousness, treatment with
rectal diazepam or lorazepam resulted in good recov-
ery of consciousness between intervals. In seizures in-
volving a loss of consciousness, none lasted longer
than 10 minutes, whereas in the 10 months prior to
implementation of the decision tree, these types of
seizures lasted for 20 minutes or more. For seizures
without a loss of consciousness, none lasted longer
than 37 minutes. No patient was hospitalized.
DISCUSSION
On review of the results from the retrospective re-
view and prospective analysis, two important con-
cepts became apparent: (1) treating epileptic seizures
as medical emergencies resulted in better patient
outcome, decreasing the frequency, duration and
severity of seizures, and reducing the risk of morbid-
ity. (2) Through the use of a detailed decision tree,
nonmedical staff can properly identify and quickly
treat seizures.
Timing: when should action be taken?
In various reports, the risk of morbidity and mortality
from epileptic seizures is strongly influence by the
duration of the seizure4, 5, 12. Prognosis is often highly
dependent on the interval of time allowed to elapse
from onset of an epileptic seizure to the start of effec-
tive treatment, and poor outcome becomes more likely
as seizure duration increases. The duration of a seizure
can be lessened and controlled with prompt and effec-
tive therapy.
Although the goal of all antiepileptic treatment
is complete seizure control, currently available
antiepileptic drugs are often unable to provide this
level of treatment. Until seizure control can be opti-
mized, the focus of emergency treatment is controlling
duration. Emergency antiepileptic treatment has been
found to be more effective when administered sooner
rather than later following seizure onset6, 7. In a study
by Lowenstein and Alldredge13, antiepileptic treat-
ment was 80% effective when administered within
the firs 30 minutes of seizure onset, but only 40%
effective when treatment was administered 2 hours
following seizure onset. This reduction in response
is a consequence of the gradual decrease in effec-
tiveness of the neurotransmitter gamma-amino-butyric
acid (GABA) and of the progressive desensitization of
GABA-ergic receptors over time14. These data under-
score the importance of treating seizures with rapid
antiepileptic drug intervention in hospital and out-
patient settings.
Proposal for a new definition of status epilepticus
In the 1980s, status epilepticus was define as a
seizure or consecutive series of seizures lasting longer
than 30 minutes or several successive seizures with-
out adequate recovery of consciousness. However,
hypoxia-induced cerebral lesions have been found to
occur in many seizures lasting only 20 minutes, and in
convulsive status epilepticus, selective cell death can
occur within the firs two to three convulsions15. In
1991, Bleck16 proposed that treatment should be initi-
ated no later than 20 minutes following seizure onset.
Two years later, the Working Group on Status Epilep-
ticus2 recommended that immediate action be taken
10 minutes following seizure onset; this is usually fol-
lowed in clinical practice today.
More recently, epileptologists have proposed a new
definitio of status epilepticus: at least 5 minutes of
continuous seizure or two or more discrete seizures
between which there is incomplete recovery of con-
sciousness17. A review of published literature as well
as the results presented in this paper indicate that
after 10 minutes, patients are at high risk for poor out-
come. This suggests that seizures should be controlled
within 10 minutes of onset by initiating treatment
within 5 minutes of seizure presentation. Therefore,
all seizures should be viewed as medical emergencies.
This concept is not yet generally accepted, and for this
reason, the term ‘prolonged seizure’ has been used in-
stead in this paper.
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Antiepileptic drug therapy accessible to
nonmedical staff
In Europe, diazepam, clobazam, clonazepam, and
lorazepam are available to nonmedical staff. Di-
azepam, and lorazepam are the most commonly used
agents for the treatment of status epilepticus. Both
are highly potent and effective when administered to
patients with active seizures2, 18. In nonhospital set-
tings, rectal and fast-dissolving doses are safe and can
be easily administered by nonmedically trained staff.
The antiseizure effect of intravenous diazepam given
rectally is reported to occur within 3 minutes8. Sublin-
gual doses of lorazepam dissolve within 20 seconds,
with onset of antiseizure effect occurring in 15 min-
utes19. Use of fast-dissolving lorazepam has multiple
advantages. These include ease of administration, con-
venience (i.e. it can be administered anywhere, given
by a careworker who works alone, given to uncooper-
ative patients), and no risk of choking. Thus, using the
decision tree, fast-dissolving lorazepam is provided
to the conscious patient during an epileptic seizure,
whereas rectal lorazepam or diazepam (intravenous
formulation) is recommended for use in patients who
have lost consciousness.
More recently, lorazepam has been considered first
line therapy for treatment of status epilepticus because
of a longer and more sustained duration of antiepilep-
tic effect. In comparison with diazepam, lorazepam
has a relatively weaker lipid solubility and smaller
volume of distribution (Vd = 12 vs. 132.7 l kg−1,
respectively)8. Lorazepam is more slowly distributed
to fatty tissues than diazepam, thereby preventing
an abrupt decline in drug concentration in the brain
and consequently reducing the risk of seizure resur-
gence2, 20. Lorazepam is also reported to be clinically
safer and more effective than diazepam21. In a study
conducted by Appleton and colleagues18, only one of
33 patients with status epilepticus required concomi-
tant antiepileptic drug therapy other than lorazepam
to control seizures. In another study, more than 80%
of patients with status epilepticus achieved seizure
control with lorazepam therapy alone22. Lastly, in con-
trast to the multiple doses and/or combination ther-
apy with other antiepileptic drugs required with di-
azepam, a single dose of lorazepam is usually suffi
cient for seizure control, reducing the risk of adverse
effects18, 20. However, lorazepam must be stored in a
refrigerator and requires dissolving before use, lead-
ing to the preferred use of diazepam when these con-
ditions cannot be met.
Historically, intravenous diazepam has been the
drug of choice for both generalized convulsive and
nonconvulsive prolonged seizures23–25, but because its
effective half-life is only 15 minutes to 4 hours, repeat
injections or continuous infusions are often required8,
thus increasing the risk of hypotension and/or respira-
tory depression26. The same is true of clobazam. Clon-
azepam may be more effective than diazepam27, but
can cause excessive salivary and bronchial secretions
that may lead to respiratory complications. Therefore,
fast-dissolving lorazepam for the conscious patient
and rectal diazepam or preferably lorazepam (intra-
venous formulation) are now recommended for first
line treatment.
CONCLUSIONS
In this study, one vial of rectally administered intra-
venous diazepam or lorazepam was sufficien to con-
trol prolonged seizures, and one fast-dissolving tablet
of lorazepam was adequate to hinder cluster seizures.
The enhanced effica y of these treatments in com-
parison to that previously reported in the literature
is related to the prompt provision of treatment (as
soon as 5 min have elapsed in patients with loss of
consciousness and as soon as 7 min have elapsed in
patients without loss of consciousness). Thus, results
of this study confir the new concept of status epilep-
ticus and that seizure-related morbidity is a function
of systematic and timely intervention. They also sug-
gest that every seizure should be treated as a med-
ical emergency. In addition, a detailed decision tree
to guide nonmedically trained caregivers in treating
seizures proved useful within nonhospital settings of
patients with proven and well-assessed epilepsy. At
the present time, the decision tree should be limited to
patients with fully assessed epilepsy. Seizures should
be treated as an emergency by lay people and care-
givers because professional medical personnel often
arrive too late. Although adopting a decision tree re-
quires careful study and implementation of a new pro-
tocol, reports from individuals involved in this study
were positive and use of the decision tree resulted in
improved clinical outcomes.
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